Skip to main content

Navigation group

Type at least 3 characters
503 articles

Articles

Original Research

Published on 02 Oct 2023

Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study

in Pediatric Immunology

  • Nizar Mahlaoui
  • Fanny Fouyssac
  • Françoise Mazingue
  • Coralie Mallebranche
  • Malika Barthez-Toullec
  • Lamia Denti
  • Kalaivani Ruhier
  • Marie-Hélène André-Bonnet
  • Aude Marie-Cardine
  • Nathalie Aladjidi
Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study
Frontiers in Pediatrics
doi 10.3389/fped.2023.1260296
  • 2,758 views
  • 1 citation